Lynda Y. Sutton

Clinical Advisory Board

 

Ms. Sutton has more than 40 years’ experience in drug development. She has lead teams working on development programs from Pre-IND stage to marketing approval for a wide range of products including small molecules, biologics and drug/device combinations.  As part of these efforts, she was instrumental in FDA marketing approval of over 25 products.  Ms. Sutton is currently President of both Cato BioVentures and Cancer Advances, serving on the boards of both companies.  She previously co-founded and was President and Chief Regulatory Officer of Cato Research LLC, which grew into a multinational CRO prior to being sold to a private equity group in 2018.  In addition to Cato Research she co-founded eight other biotechnology or service companies that had successful exits through mergers or acquisitions.  Ms. Sutton has been a frequent speaker at a wide range of industry conferences.  She is known for her expertise in regulatory strategy and finding creative solutions to issues that arise during development of drugs, biologics or devices.